Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2, Randomized Study to Evaluate the Safety, Efficacy and Optimal dose of ABBV-400 in Combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (mCRC)
NCT Number:
NCT06107413
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Colon
Study Objectives:
To optimize ABBV-400 dose in combination with 5-FU, folinic acid, and bevacizumab to
determine the RP3D regimen for the combination. To evaluate the efficacy as measured by OR and PFS of ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab, To evaluate the safety and tolerability of ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab.
Study Documents
(MUSC NetID required for document access)